Novo Nordisk Invented the Weight-Loss Era. Then It Lost the Lead — and Not to a Better Drug.

Semaglutide was Novo's molecule, and Novo's moment. It launched as the diabetes drug Ozempic in 2017 and as the obesity drug Wegovy in 2021, and it did something drugs almost never do: it escaped the pharmacy and entered the culture. Talk-show monologues. A word — "Ozempic" — that became a verb. Novo didn't just lead the obesity market; it was the obesity market. By the summer of 2024 that dominance had made a Danish insulin maker larger than LVMH, the most valuable listed company on the continent.¹

Two years later, the company that created the biggest new drug market in a generation is the one losing it. The tidy explanation is chemistry: Lilly's tirzepatide takes off more weight than Novo's semaglutide, so Lilly won. And the head-to-head numbers back it — in the 72-week SURMOUNT-5 trial reported in December 2024, Lilly's Zepbound delivered 20.2% average weight loss against Wegovy's 13.7%.⁴ Better molecule, better result, game over.

Except that's not how markets this big are won or lost. Novo had a two-year head start, the only household-name brands in the category, and a market growing faster than either company could serve. A head start that large is not surrendered because your rival's drug is a few points stronger. It's surrendered when you can't make enough of your own — and when the one bet meant to leapfrog the rival merely ties. That is what actually happened, and both halves were closer to a choice than to bad luck.

The follow-up that had to leap, and only tied: what a knockout punch looks like when it lands as a handshake

Novo knew semaglutide would eventually be out-gunned, so it built its second act: CagriSema, a combination of semaglutide with a second molecule, cagrilintide. The pitch to investors was explicit — this would be the drug that vaulted Novo back ahead, with weight loss around 25%.⁵ The whole strategy leaned on it. Retake the efficacy crown, and the head start does the rest.

In December 2024, the pivotal REDEFINE 1 results arrived: about 22.7% weight loss — a genuinely powerful result, and a strategic disaster.⁵ Not because 22.7% is bad, but because it wasn't the leap Novo had promised or the market had priced. It roughly matched what Lilly already sold. Novo's stock fell about 20% in a single session; the number that was supposed to end the contest instead confirmed Novo had drawn level, at best, with a rival already pulling ahead.⁵ The knockout punch landed as a handshake.

The market it created, and couldn't fill: a supply you can't meet invites copycats and hands your rival room to scale

Here is the half of the story that never makes the headline, and matters more than the trial data. From 2022 onward, demand for these drugs wasn't a market — it was a stampede. And Novo could not make enough. Wegovy sat on the U.S. Food and Drug Administration's official shortage list, and under U.S. rules a listed shortage does something specific: it makes it legal for compounding pharmacies to sell their own copies of the drug.⁶ For roughly two years, telehealth sites sold compounded semaglutide to millions of patients Novo could have had — legal copycats, filling the gap Novo's own factories left open.⁶

Novo understood the problem cold. In February 2024 its parent, Novo Holdings, agreed to buy the contract manufacturer Catalent for $16.5 billion — an enormous check whose entire purpose was to bolt on the fill-finish capacity to make more Wegovy.⁷ That deal is the confession: the binding constraint on the world's most valuable drug company was never the science. It was the number of pens it could fill. And by the time the capacity arrived, Lilly had spent the same window pouring billions into manufacturing ahead of demand — converting the stampede into its prescriptions while Novo rationed.

The two failures compound. A supply you can't meet invites copycats and hands your rival room to scale. A follow-up that ties instead of leaps means that when the copycats are finally cleared out, the branded customer has a better reason to pick the other brand. Novo lost the top and the bottom of its own market at the same time.

The scoreboard is not subtle. In January 2025 Novo lost its crown as Europe's most valuable company.⁸ In May 2025 the board parted ways with CEO Lars Fruergaard Jørgensen.⁹ By late 2025 Lilly crossed a trillion dollars in market value, the first healthcare company ever to do so, with tirzepatide the best-selling drug in the world.²³ Novo, the company that named the era, guided to shrinking sales and announced it would cut about 9,000 jobs — roughly 11% of its workforce.³¹⁰

The honest objection

"You're overcomplicating it. Lilly's molecule is simply better — that's chemistry, not strategy." The molecule is better, and that matters. But being second on efficacy is not fatal when you are two years ahead, own the famous names, and sell into a market expanding faster than anyone can supply — unless you also can't manufacture enough and your one big follow-up fails to pull ahead. Novo controlled the timing, the brand, and the category. It lost on the two things that were genuinely its to decide: how much to invest in capacity, and where to place the follow-up bet. Chemistry set the terms. Strategy lost the lead.

"The shortage wasn't a choice — you can't build biologic capacity overnight." Fair, and true. But Lilly faced the identical physics and chose to spend into it early; Novo chose to protect margins and bank on a moonshot, then buy capacity once the damage was visible. When two companies meet the same constraint and one prepares for it a year sooner, the difference between them isn't luck. It's the strategy.

The read

Novo Nordisk's fall gets filed as a stumble by a great company that will surely recover. Maybe it will. But the lesson underneath is colder and more portable than "the better drug wins." In an ordinary market, the superior product usually does. In a demand shock — a market that explodes faster than anyone can serve it — the prize goes to whoever can make the most and bet the surest. The science is table stakes. Capacity and nerve are the moat.

Novo proved something rare and expensive: you can invent a market, own its language, lead it by years — and still lose it, by treating a gold rush like a luxury launch.

Some figures here trace to company guidance and secondary reporting rather than a single primary filing — notably the ~25% CagriSema expectation and the ~22.7% readout reported at the December 2024 announcement, and U.S. obesity market-share figures. They are attributed as reported and cross-checked across outlets.